Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
Quintela-Fandino, M., Manso Sànchez, L.M., Holgado Martín, E., Moreno, M.C., Morales Murillo, S., Bermejo De Las Heras, B., Malon Gimenez, D., Colomer Bosch, R., Gonzalez Cortijo, L., Hornedo, J., Mouron, S., Muñoz, M., Escudero, S., Blanco, R., Mañes, S.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
1871P Overcoming barriers in opioid-induced constipation management
Holgado Martín, E., Blasco Cordellat, A., García-Castaño, A., Villatoro, R., Guix Arnau, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
Quintela-Fandino, M, Manso Sànchez, L M, Holgado Martín, E, Moreno, M C, Morales Murillo, S, Bermejo De Las Heras, B, Malon Gimenez, D, Colomer Bosch, R, Gonzalez Cortijo, L, Hornedo, J, Mouron, S, Muñoz, M, Escudero, S, Blanco, R, Mañes, S
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
Rugo, H.S., Cescon, D.W., Im, S-A., Yusof, M. Md, Araneda, C.E. Gallardo, Lipatov, O., Cruz, F., Barrios, C.H., Hegg, R., Martín, E. Holgado, Torregroza Otero, M.A., Turner, N., Árkosy, P.F., Tarnawski, R., Karantza, V., Pan, W., Guo, Z., Cortés, J.
Published in ESMO open (01.05.2023)
Published in ESMO open (01.05.2023)
Get full text
Journal Article